


ASG, 38 aa



Dal 19/05/2018 al 22/06/2018 eseguita EBRT con tecnica VMAT sulla pelvi; dose totale 45 Gy/25 frazioni con SIB a 55 Gy sul linfonodo PET-positivo, in associazione a 5 cicli di CDDP radiosensibilizzante.






ASG, 38 aa

21/06/18 RM addome inferiore senza mdc (rivalutazione pre-BRT)

Rispetto a marzo 2018, si osserva una netta riduzione dimensionale del noto tessuto patologico localizzato a livello della cervice.

Al controllo odierno persiste un tessuto residuo in sede posteriore, del diametro cranio-caudale di 1 cm.

Netta riduzione dimensionale anche dell'adenopatia iliaco-otturatoria destra.





ASG, 38 aa

25/06/2018 *Visita pre-BRT*






GE regolari, vagina abbastanza elastica, con mucosa eritematosa; la cervice, di dimensioni ridotte, presenta area centrale, posteriore rispetto all'OUE, necrotica, la restante mucosa appare eritematosa, con qualche teleangectasia.

Parametri stirati, non nodulari.

Patient: ASG

Clinical Drawing

At Brachytherapy



dd/mm/yy
 25 / 06 / 18



Fondazione IRCCS
 Istituto Nazionale dei
 Tumori di Milano




Associazione Italiana
 Radioterapia e Oncologia clinica



Società Italiana di Radiobiologia



BOLOGNA, 25-27 NOVEMBRE
 PALAZZO DEI CONGRESSI



EDITORIAL

Curative Radiation Therapy for Locally Advanced Cervical Cancer: Brachytherapy Is NOT Optional

Kari Tanderup, PhD,^{*,†} Patricia J. Eifel, MD,[‡] Catheryn M. Yashar, MD,[§]
Richard Pötter, MD,^{||} and Perry W. Grigsby, MD^{*}

**Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; †Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; ‡Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; §Department of Radiation Oncology, University of California, San Diego, La Jolla, California; and ||Department of Radiotherapy and Oncology, Comprehensive Cancer Center and Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria*

Received Nov 5, 2013. Accepted for publication Nov 6, 2013.

International Journal of
Radiation Oncology
biology • physics



Fondazione IRCCS
Istituto Nazionale dei
Tumori di Milano




Associazione Italiana
Radioterapia e Oncologia clinica



Società Italiana di Radiobiologia



BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI



● Contouring



Radiotherapy and Oncology 74 (2005) 235–245



Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group[☆] (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV

Christine Haie-Meder^{a,*}, Richard Pötter^b, Erik Van Limbergen^c, Edith Briot^d,
Marisol De Brabandere^c, Johannes Dimopoulos^b, Isabelle Dumas^a, Taran Paulsen Hellebust^d,
Christian Kirisits^b, Stefan Lang^b, Sabine Muschitz^b, Juliana Nevinson^e, An Nulens^c,
Peter Petrow^f, Natascha Wachter-Gerstner^b

Radiotherapy and Oncology 78 (2006) 67–77
www.thegreenjournal.com

● Reporting

ESTRO project

Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology

Richard Pötter^{a,*}, Christine Haie-Meder^b, Erik Van Limbergen^c, Isabelle Barillot^d,
Marisol De Brabandere^c, Johannes Dimopoulos^a, Isabelle Dumas^b, Beth Erickson^e,
Stefan Lang^a, An Nulens^c, Peter Petrow^f, Jason Rownd^g, Christian Kirisits^a



Fondazione IRCCS
Istituto Nazionale dei
Tumori di Milano



Associazione Italiana
Radioterapia e Oncologia clinica



Società Italiana di Radiobiologia



BOLOGNA, 25-27 NOVEMBRE
PALAZZO DEI CONGRESSI

● Applicator reconstruction



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



GEC-ESTRO Recommendations

Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy

Taran Paulsen Hellebust^{a,*}, Christian Kirisits^b, Daniel Berger^b, José Pérez-Calatayud^c, Marisol De Brabandere^d, Astrid De Leeuw^e, Isabelle Dumas^f, Robert Hudej^g, Gerry Lowe^h, Rachel Wills^h, Kari Tanderupⁱ

● Imaging



Contents lists available at SciVerse ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com





GEC-ESTRO Recommendations

Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy

Johannes C.A. Dimopoulos^a, Peter Petrow^b, Kari Tanderup^c, Primož Petric^d, Daniel Berger^e, Christian Kirisits^e, Erik M. Pedersen^c, Erik van Limbergen^f, Christine Haie-Meder^g, Richard Pötter^{e,*}









ASG, 38 aa

BRACHITERAPIA CERVICO-VAGINALE

Dal 25/06/18 al 05/07/18 eseguito trattamento BRT-HDR su regione cervico-vaginale, dose 28 Gy in 4 frazioni, a guida di immagine di RM.







ASG, 38 aa


BRACHITERAPIA CERVICO-VAGINALE

Dal 25/06/18 al 05/07/18 eseguito trattamento BRT-HDR su regione cervico-vaginale, dose 28 Gy in 4 frazioni, a guida di immagine di RM.







ASG, 38 aa



GTV- res




HR-CTV




IR-CTV






ASG, 38 aa





PHYSICAL - BIOLOGICAL DOCUMENTATION OF GYNAECOLOGICAL HDR BT							Version: 22/11/20	
PATIENT, ID-number		ASG				tumour entity	exophytic	
EXTERNAL BEAM THERAPY			TUMOUR		OAR	FIGO, TNM	IIIC1	
dose per fraction	1,8	D _{iso} [$\alpha/\beta=10$ Gy]		D _{iso} [$\alpha/\beta=3$ Gy]				
fractions without central shield	25	44,3		43,2				
fractions with central shield	0	0,0		0,0		GTV at diag.	28.5 cm ³	
total dose	45,0	44,3		43,2		chemoth.	CDDP	
Total volume (body contour) treated to 43 Gy	[cm ³]	186						
Total volume (body contour) treated to 57 Gy	[cm ³]	18,7						
BRACHYTHERAPY			F 1	F 2	F 3	F 4	F 5	F 6
date	25.6.2018	29.6.2018	2.7.2018	5.7.2018				
physicist								
MR / CT	MRI	MRI	MRI	MRI				
applicator(s): type, # needles	Ring	Ring	Ring	Ring, 1 needle			TOTAL BT	TOTAL BT + EBT
applicator(s): dimensions	26 mm	26 mm	26 mm	26 mm			mean	stddev
Plan, remarks								
GTV _{res} [cm ³]	2,1	1,55	1,78	1,25			1,7	0,3
D ₉₈	13,6	10,1	9,0	8,9				
D ₉₈ EQD2 ₁₀	26,8	16,9	14,1	14,1	0,0	0,0	71,9	116,2
CTV _{HR} [cm ³]	17,69	19,19	24,82	26,23			22,0	3,6
D ₉₈	5,7	6,2	6,1	5,6				
D ₉₈ EQD2 ₁₀	7,6	8,2	8,1	7,5	0,0	0,0	31,3	75,6
D ₉₀	7,6	8,2	8,1	7,5				
D ₉₀ EQD2 ₁₀	9,5	10,2	10,1	9,4			41,5	85,8
D ₅₀	1,1	1,2	1,2	1,1				
D ₅₀ EQD2 ₁₀	2,2	2,4	2,4	2,2			85,3	129,5
		Target	D90 CTV_{HR} EQD2₁₀	D98 CTV_{HR} EQD2₁₀	D98 GTV_{res} EQD2₁₀			
		Planning Aims	> 90 Gy < 95 Gy	> 75 Gy	>95 Gy			
		Limits for Prescribed Dose	> 85 Gy	-	>90 Gy			






PHYSICAL - BIOLOGICAL DOCUMENTATION OF GYNAECOLOGICAL HDR BT								Version: 22/11/
BLADDER [cm³]	163,9	134,6	332,9	312,2			235,9	87,6
Bladder reference point	2,6	4,8	3,6	3,1				
ICRU EQD2 ₃	3,0	7,5	4,8	3,7	0,0	0,0	19,1	62,3
D _{0.1cm³}	5,9	5,9	6,8	6,8				
D _{0.1cm³} EQD2 ₃	10,5	10,6	13,4	13,2	0,0	0,0	47,7	90,9
D _{2cm³}	4,2	4,7	5,0	5,6				
D _{2cm³} EQD2 ₃	6,0	7,3	7,9	9,6	0,0	0,0	30,8	74,0
RECTUM [cm³]	25,1	5,5	51,3	9,1			22,8	18,1
Recto-vaginal reference point	1,7	3,4	4,5	3,2				
ICRU EQD2 ₃	1,5	4,3	6,7	3,9	0,0	0,0	16,4	59,6
D _{0.1cm³}	2,0	1,7	7,0	2,3				
D _{0.1cm³} EQD2 ₃	2,0	1,5	14,1	2,5	0,0	0,0	20,1	63,3
D _{2cm³}	1,3	1,0	4,3	1,5				
D _{2cm³} EQD2 ₃	1,1	0,8	6,3	1,4	0,0	0,0	9,5	52,7
SIGMOID [cm³]	99,3	141,1	95,9	95,4			107,9	19,2
D _{0.1cm³}	5,7	6,0	6,4	5,5				
D _{0.1cm³} EQD2 ₃	9,8	10,7	11,9	9,3	0,0	0,0	41,7	84,9
D _{2cm³}	3,5	4,5	4,5	4,1				
D _{2cm³} EQD2 ₃	4,5	6,8	6,8	5,9	0,0	0,0	24,0	67,2
INTESTINES OR BOWEL [cm³]	0	0	0	0			0,0	0,0
D _{0.1cm³}	0,0	0,0	0,0	0,0				
D _{0.1cm³} EQD2 ₃	0,0	0,0	0,0	0,0	0,0	0,0	0,0	43,2
D _{2cm³}	0,0	0,0	0,0	0,0				
D _{2cm³} EQD2 ₃	0,0	0,0	0,0	0,0	0,0	0,0	0,0	43,2

OAR	Bladder D2cm ³ EQD23	Rectum D2cm ³ EQD23	Recto- vaginal point EQD23	Sigmoid D2cm ³ EQD23	Bowel D2cm ³ EQD23
Planning Aims	< 80 Gy	< 65 Gy	< 65 Gy	< 70 Gy*	< 70 Gy*
Limits for Prescribed Dose	< 90 Gy	< 75 Gy	< 75 Gy	< 75 Gy*	< 75 Gy*





ASG, 38 aa

17/08/2022 ULTIMO FUP

TAC T-A-P con e senza mdc (27/7/2022): oncologicamente negativa
RM pelvi con e senza mdc ((01/08/2022): oncologicamente negativa

Soggettivamente bene, non riferisce episodi di sanguinamento vaginale, non disturbi

Esame obiettivo: Genitali esterni regolari. Vagina anelastica in esiti RT, cervice annullata, utero ipomobile . Parametri e retto liberi all'esplorazione retto-vaginale.

ES: portio annullata, atrofia. Non perdite vaginali.

COLPOSCOPIA: non aree acetoreattive



NED

